Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853553 · ClinicalTrials.gov registry record · Phase 3
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 3 study of ADPKD, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT01853553 is a Phase 3 study of ADPKD that has completed, run by University of Colorado, Denver. The registered enrollment target is 61 participants, below the 225-participant average among 3 other ADPKD trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01853553, a Phase 3 study of ADPKD, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed research will determine the effectiveness of blocking aldosterone for improving the health and function of arteries in patients with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how blocking aldosterone improves artery health by determining the physiological mechanisms (biological reasons) involved. Overall, the proposed research will provide important new scientific evidence upon which physicians can base recommendations to patients with ADPKD to decrease risk of developing cardiovascular diseases.
Conditions Studied
Interventions
- DRUG Spironolactone
- DRUG Sugar pill
Study Locations (1)
Colorado
- UColorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01853553
The ClinicalTrials.gov registry entry for NCT01853553 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 3 other ADPKD trials with a reported enrollment target (73% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ADPKD appearing as the primary indexed condition, and to 2 interventions - of which Spironolactone is the first listed.
NCT01853553 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01853553 about?
NCT01853553 is a clinical study titled "Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)". The proposed research will determine the effectiveness of blocking aldosterone for improving the health and function of arteries in patients with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how blocking aldosterone improves artery health by determin...
What is the current status of trial NCT01853553?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2013-07. Estimated completion is 2017-01.
What conditions does trial NCT01853553 study?
This clinical trial studies the following conditions: ADPKD.
What interventions are being tested in trial NCT01853553?
The interventions under investigation include: Spironolactone (DRUG), Sugar pill (DRUG).
Who is sponsoring clinical trial NCT01853553?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01853553 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADPKD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.